{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T12:27:55Z","timestamp":1785155275039,"version":"3.55.0"},"reference-count":35,"publisher":"Pharmaceutical Society of Japan","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological & Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2021,11,1]]},"DOI":"10.1248\/bpb.b21-00474","type":"journal-article","created":{"date-parts":[[2021,10,31]],"date-time":"2021-10-31T22:09:17Z","timestamp":1635718157000},"page":"1746-1751","source":"Crossref","is-referenced-by-count":6,"title":["Involvement of the Peripheral \u03bc-Opioid Receptor in Tramadol-Induced Constipation in Rodents"],"prefix":"10.1248","volume":"44","author":[{"given":"Kana","family":"Yasufuku","sequence":"first","affiliation":[{"name":"Laboratory for Drug Discovery and Disease Research, Shionogi & Co., Ltd."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsumi","family":"Koike","sequence":"additional","affiliation":[{"name":"Laboratory for Drug Discovery and Disease Research, Shionogi & Co., Ltd."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mika","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Research Area for Pharmacological Evaluation, Shionogi TechnoAdvance Research Co., Ltd."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Chiba","sequence":"additional","affiliation":[{"name":"Research Area for Pharmacological Evaluation, Shionogi TechnoAdvance Research Co., Ltd."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motoji","family":"Kitaura","sequence":"additional","affiliation":[{"name":"General Administration Division, Shionogi Administration Service Co., Ltd."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shino","family":"Takenouchi","sequence":"additional","affiliation":[{"name":"Transgenic and Breeding Technology, Shionogi TechnoAdvance Research Co., Ltd."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minoru","family":"Hasegawa","sequence":"additional","affiliation":[{"name":"Laboratory for Drug Discovery and Disease Research, Shionogi & Co., Ltd."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhide","family":"Morioka","sequence":"additional","affiliation":[{"name":"Medical Affairs Department, Shionogi & Co., Ltd."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Mishima","sequence":"additional","affiliation":[{"name":"Medical Affairs Department, Shionogi & Co., Ltd."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsutomu","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, School of Pharmacy, Shonan University of Medical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahide","family":"Fujita","sequence":"additional","affiliation":[{"name":"Laboratory for Drug Discovery and Disease Research, Shionogi & Co., Ltd."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"163","reference":[{"key":"1","unstructured":"1) Swegle JM, Logemann C. Management of common opioid-induced adverse effects. Am. Fam. Physician<\/i>, 74<\/b>, 1347\u20131354 (2006)."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Benyamin R, Trescot AM, Datta S, Buenaventura R, Adlaka R, Sehgal N, Glaser SE, Vallejo R. Opioid complications and side effects. Pain Physician<\/i>, 11<\/b> (Suppl.), S105\u2013S120 (2008).","DOI":"10.36076\/ppj.2008\/11\/S105"},{"key":"3","unstructured":"3) Raffa RB, Friderichs E, Reimann W, Shank RP, Codd EE, Vaught JL. Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an \u2018atypical\u2019 opioid analgesic. J. Pharmacol. Exp. Ther.<\/i>, 260<\/b>, 275\u2013285 (1992)."},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Desmeules JA, Piguet V, Collart L, Dayer P. Contribution of monoaminergic modulation to the analgesic effect of tramadol. Br. J. Clin. Pharmacol.<\/i>, 41<\/b>, 7\u201312 (1996).","DOI":"10.1111\/j.1365-2125.1996.tb00152.x"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Gillen C, Haurand M, Kobelt DJ, Wnendt S. Affinity, potency and efficacy of tramadol and its metabolites at the cloned human mu-opioid receptor. Naunyn Schmiedebergs Arch. Pharmacol.<\/i>, 362<\/b>, 116\u2013121 (2000).","DOI":"10.1007\/s002100000266"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Avouac J, Gossec L, Dougados M. Efficacy and safety of opioids for osteoarthritis: a meta-analysis of randomized controlled trials. Osteoarthritis Cartilage<\/i>, 15<\/b>, 957\u2013965 (2007).","DOI":"10.1016\/j.joca.2007.02.006"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Christensen HN, Olsson U, From J, Breivik H. Opioid-induced constipation, use of laxatives, and health-related quality of life. Scand. J. Pain<\/i>, 11<\/b>, 104\u2013110 (2016).","DOI":"10.1016\/j.sjpain.2015.12.007"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Langley PC, Patkar AD, Boswell KA, Benson CJ, Schein JR. Adverse event profile of tramadol in recent clinical studies of chronic osteoarthritis pain. Curr. Med. Res. Opin.<\/i>, 26<\/b>, 239\u2013251 (2010).","DOI":"10.1185\/03007990903426787"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Minami K, Ogata J, Uezono Y. What is the main mechanism of tramadol? Naunyn Schmiedebergs Arch. Pharmacol.<\/i>, 388<\/b>, 999\u20131007 (2015).","DOI":"10.1007\/s00210-015-1167-5"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Minami K, Uezono Y, Ueta Y. Pharmacological aspects of the effects of tramadol on G-protein coupled receptors. J. Pharmacol. Sci.<\/i>, 103<\/b>, 253\u2013260 (2007).","DOI":"10.1254\/jphs.CR0060032"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Bigal LM, Bibeau K, Dunbar S. Tramadol Prescription over a 4-Year Period in the USA. Curr. Pain Headache Rep.<\/i>, 23<\/b>, 76 (2019).","DOI":"10.1007\/s11916-019-0777-x"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Hider-Mlynarz K, Cavali\u00e9 P, Maison P. Trends in analgesic consumption in France over the last 10 years and comparison of patterns across Europe. Br. J. Clin. Pharmacol.<\/i>, 84<\/b>, 1324\u20131334 (2018).","DOI":"10.1111\/bcp.13564"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Kalkman GA, Kramers C, van Dongen RT, van den Brink W, Schellekens A. Trends in use and misuse of opioids in the Netherlands: a retrospective, multi-source database study. Lancet Public Health<\/i>, 4<\/b>, e498\u2013e505 (2019).","DOI":"10.1016\/S2468-2667(19)30128-8"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Hurtado I, Garc\u00eda-Sempere A, Peir\u00f3 S, Sanf\u00e9lix-Gimeno G. Increasing trends in opioid use from 2010 to 2018 in the region of Valencia, Spain: a real-world, population-based study. Front. Pharmacol.<\/i>, 11<\/b>, 612556 (2020).","DOI":"10.3389\/fphar.2020.612556"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Blair HA. Naldemedine: a review in opioid-induced constipation. Drugs<\/i>, 79<\/b>, 1241\u20131247 (2019).","DOI":"10.1007\/s40265-019-01160-7"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Kanemasa T, Koike K, Arai T, Ono H, Horita N, Chiba H, Nakamura A, Morioka Y, Kihara T, Hasegawa M. Pharmacologic effects of naldemedine, a peripherally acting \u03bc-opioid receptor antagonist, in in vitro<\/i> and in vivo<\/i> models of opioid-induced constipation. Neurogastroenterol. Motil.<\/i>, 31<\/b>, e13563 (2019).","DOI":"10.1111\/nmo.13563"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Nakamura A, Hasegawa M, Ito H, Minami K, Koike K, Habu-Tomita N, Nanba K, Hamaguchi K, Noshi E, Hashimoto H, Nishino I, Okabayashi Y, Koyabu K, Kihara T, Iwamoto Y, Inoue Y, Narita M, Suzuki T, Kato A. Distinct relations among plasma concentrations required for different pharmacological effects in oxycodone, morphine, and fentanyl. J. Pain Palliat. Care Pharmacother.<\/i>, 25<\/b>, 318\u2013334 (2011).","DOI":"10.3109\/15360288.2011.620689"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Th\u00f6rn SE, Wattwil M, Lindberg G, S\u00e4we J. Systemic and central effects of morphine on gastroduodenal motility. Acta Anaesthesiol. Scand.<\/i>, 40<\/b>, 177\u2013186 (1996).","DOI":"10.1111\/j.1399-6576.1996.tb04417.x"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Corona-Ramos JN, De la O-Arciniega M, D\u00e9ciga-Campos M, Medina-L\u00f3pez JR, Dom\u00ednguez-Ram\u00edrez AM, Jaramillo-Morales OA, Espinosa-Ju\u00e1rez JV, L\u00f3pez-Mu\u00f1oz FJ. The antinociceptive effects of tramadol and\/or gabapentin on rat neuropathic pain induced by a chronic constriction injury. Drug Dev. Res.<\/i>, 77<\/b>, 217\u2013226 (2016).","DOI":"10.1002\/ddr.21313"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Kaneko K, Umehara M, Homan T, Okamoto K, Oka M, Oyama T. The analgesic effect of tramadol in animal models of neuropathic pain and fibromyalgia. Neurosci. Lett.<\/i>, 562<\/b>, 28\u201333 (2014).","DOI":"10.1016\/j.neulet.2014.01.007"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Parasrampuria R, Vuppugalla R, Elliott K, Mehvar R. Route-dependent stereoselective pharmacokinetics of tramadol and its active O-demethylated metabolite in rats. Chirality<\/i>, 19<\/b>, 190\u2013196 (2007).","DOI":"10.1002\/chir.20360"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Godoy AL, De Moraes NV, Martinez EZ, Carvalho TM, Marques MP, Lanchote VL. Simultaneous analysis of tramadol, O-desmethyltramadol, and N-desmethyltramadol enantiomers in rat plasma by high performance liquid chromatography-tandem mass spectrometry: application to pharmacokinetics. Chirality<\/i>, 23<\/b>, 287\u2013293 (2011).","DOI":"10.1002\/chir.20914"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Ardakani YH, Rouini MR. Improved liquid chromatographic method for the simultaneous determination of tramadol and its three main metabolites in human plasma, urine and saliva. J. Pharm. Biomed. Anal.<\/i>, 44<\/b>, 1168\u20131173 (2007).","DOI":"10.1016\/j.jpba.2007.04.012"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Leppert W. Tramadol as an analgesic for mild to moderate cancer pain. Pharmacol. Rep.<\/i>, 61<\/b>, 978\u2013992 (2009).","DOI":"10.1016\/S1734-1140(09)70159-8"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) D\u00fcrsteler C, Mases A, Fernandez V, Pol O, Puig MM. Interaction between tramadol and two anti-emetics on nociception and gastrointestinal transit in mice. Eur. J. Pain<\/i>, 10<\/b>, 629\u2013638 (2006).","DOI":"10.1016\/j.ejpain.2005.10.002"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Evangelista Vaz R, Draganov DI, Rapp C, Avenel F, Steiner G, Arras M, Bergadano A. Preliminary pharmacokinetics of tramadol hydrochloride after administration via<\/i> different routes in male and female B6 mice. Vet. Anaesth. Analg.<\/i>, 45<\/b>, 111\u2013122 (2018).","DOI":"10.1016\/j.vaa.2016.09.007"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Bharucha AE, Lacy BE. Mechanisms, evaluation, and management of chronic constipation. Gastroenterology<\/i>, 158<\/b>, 1232\u20131249.e3 (2020).","DOI":"10.1053\/j.gastro.2019.12.034"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Ford AC, Brandt LJ, Young C, Chey WD, Foxx-Orenstein AE, Moayyedi P. Efficacy of 5-HT 3 antagonists and 5-HT 4 agonists in irritable bowel syndrome: systematic review and meta-analysis. Am. J. Gastroenterol.<\/i>, 104<\/b>, 1831\u20131843, quiz, 1844 (2009).","DOI":"10.1038\/ajg.2009.223"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Shiga Y, Minami KMD, Shiraishi M, Uezono YMD, Murasaki O, Kaibara M, Shigematsu A. The inhibitory effects of tramadol on muscarinic receptor-induced responses in xenopus oocytes expressing cloned M3 Receptors. Anesth. Analg.<\/i>, 95<\/b>, 1269\u20131273 (2002).","DOI":"10.1097\/00000539-200211000-00031"},{"key":"30","unstructured":"30) Eglen RM, Hegde SS, Watson N. Muscarinic receptors and smooth muscle function. Pharmacol. Rev.<\/i>, 48<\/b>, 531\u2013565 (1996)."},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Chapple C, Steers W, Norton P, Millard R, Kralidis G, Glavind K, Abrams P. A pooled analysis of three phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of overactive bladder. BJU Int.<\/i>, 95<\/b>, 993\u20131001 (2005).","DOI":"10.1111\/j.1464-410X.2005.05454.x"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Imam MZ, Kuo A, Ghassabian S, Smith MT. Progress in understanding mechanisms of opioid-induced gastrointestinal adverse effects and respiratory depression. Neuropharmacology<\/i>, 131<\/b>, 238\u2013255 (2018).","DOI":"10.1016\/j.neuropharm.2017.12.032"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Holzer P. Opioid receptors in the gastrointestinal tract. Regul. Pept.<\/i>, 155<\/b>, 11\u201317 (2009).","DOI":"10.1016\/j.regpep.2009.03.012"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Mori T, Shibasaki Y, Matsumoto K, Shibasaki M, Hasegawa M, Wang E, Masukawa D, Yoshizawa K, Horie S, Suzuki T. Mechanisms that underlie \u03bc-opioid receptor agonist\u2013induced constipation: differential involvement of \u03bc-opioid receptor sites and responsible regions. J. Pharmacol. Exp. Ther.<\/i>, 347<\/b>, 91\u201399 (2013).","DOI":"10.1124\/jpet.113.204313"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Matsumoto K, Umemoto H, Mori T, Akatsu R, Saito S, Tashima K, Shibasaki M, Kato S, Suzuki T, Horie S. Differences in the morphine-induced inhibition of small and large intestinal transit: Involvement of central and peripheral \u03bc-opioid receptors in mice. Eur. J. Pharmacol.<\/i>, 771<\/b>, 220\u2013228 (2016).","DOI":"10.1016\/j.ejphar.2015.12.033"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/44\/11\/44_b21-00474\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,6]],"date-time":"2021-11-06T03:52:19Z","timestamp":1636170739000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/44\/11\/44_b21-00474\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,1]]},"references-count":35,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b21-00474","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,1]]},"article-number":"b21-00474"}}